Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TSHA 
Taysha Gene Therapies Inc (TSHA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TSHA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $8.67
1 Year Target Price $8.67
| 7 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -66.95% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 802.02M USD | Price to earnings Ratio - | 1Y Target Price 8.67 |
Price to earnings Ratio - | 1Y Target Price 8.67 | ||
Volume (30-day avg) 10 | Beta 0.96 | 52 Weeks Range 1.05 - 3.31 | Updated Date 08/15/2025 |
52 Weeks Range 1.05 - 3.31 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.34 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.08 | Actual -0.09 |
Profitability
Profit Margin - | Operating Margin (TTM) -1347.08% |
Management Effectiveness
Return on Assets (TTM) -20.88% | Return on Equity (TTM) -51.86% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 548852961 | Price to Sales(TTM) 99.04 |
Enterprise Value 548852961 | Price to Sales(TTM) 99.04 | ||
Enterprise Value to Revenue 67.78 | Enterprise Value to EBITDA -0.61 | Shares Outstanding 272795008 | Shares Floating 173914505 |
Shares Outstanding 272795008 | Shares Floating 173914505 | ||
Percent Insiders 11.19 | Percent Institutions 67.76 |
Upturn AI SWOT
Taysha Gene Therapies Inc
Company Overview
History and Background
Taysha Gene Therapies, Inc. was founded in 2019. It focuses on developing and commercializing AAV-based gene therapies for monogenic diseases of the central nervous system. The company went public in 2020.
Core Business Areas
- Gene Therapy Development: Taysha Gene Therapies focuses on the discovery, development, and commercialization of gene therapies for the treatment of monogenic diseases of the central nervous system (CNS).
Leadership and Structure
RA Session II is the President, CEO and Founder. The company has a typical biotech structure with R&D, clinical development, and commercial functions.
Top Products and Market Share
Key Offerings
- TSHA-101: An AAV9 gene therapy targeting GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases). Clinical trials are underway. No market share yet. Competitors are companies developing therapies for lysosomal storage disorders.
- TSHA-102: An AAV9 gene therapy for Rett syndrome. Preclinical studies are underway. No market share yet. Competitors are companies developing therapies for Rett syndrome
- TSHA-120: Giant axonal neuropathy. Clinical Trials are underway. No market share yet. Competitors are companies developing therapies for giant axonal neuropathy.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by technological advancements and increasing success rates in clinical trials. There is high unmet need for treatments of rare diseases.
Positioning
Taysha is a clinical-stage gene therapy company focused on CNS disorders. Its competitive advantage lies in its AAV9 platform and focus on rare monogenic diseases.
Total Addressable Market (TAM)
The total addressable market for gene therapies is estimated to reach billions of dollars. Taysha is positioned to capture a share of this market by addressing unmet needs in specific CNS disorders.
Upturn SWOT Analysis
Strengths
- Strong AAV9 platform
- Focus on rare monogenic CNS diseases
- Experienced management team
- Strong intellectual property position
Weaknesses
- Clinical trial risk
- High cash burn rate
- Reliance on external manufacturing partners
- Not yet commercially available
Opportunities
- Positive clinical trial results
- FDA approval and commercialization of gene therapies
- Expansion into new disease areas
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other gene therapy companies
- Adverse events associated with gene therapy
Competitors and Market Share
Key Competitors
- BLUE
- CRSP
- EDIT
Competitive Landscape
Taysha competes with other gene therapy companies, as well as companies developing alternative treatments for CNS disorders. Key competitive factors include the safety and efficacy of gene therapies, as well as regulatory approval and commercialization.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pipeline advancement, clinical trial initiations, and fundraising activities.
Future Projections: Future growth depends on the successful development and commercialization of its gene therapies. Analyst estimates vary, but generally positive if their clinical trials are successful.
Recent Initiatives: Recent initiatives include advancing lead programs into later-stage clinical trials and expanding the pipeline through licensing and acquisitions.
Summary
Taysha Gene Therapies is a clinical-stage gene therapy company with a promising AAV9 platform targeting rare CNS disorders. The company's success hinges on positive clinical trial results and regulatory approval of its lead programs. Its high cash burn rate and reliance on external manufacturing are key risks to watch. The company is positioned in a growing market but must differentiate itself from other competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investing in biotech companies involves significant risks, including clinical trial failure and regulatory uncertainty.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Taysha Gene Therapies Inc
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2020-09-24 | CEO & Chairman Mr. Sean P. Nolan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 73 | Website https://www.tayshagtx.com |
Full time employees 73 | Website https://www.tayshagtx.com | ||
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.